Results for Glatiramer Acetate (GA) Depot 3 year analysis in RRMS, GA Depot safety results in RRMS and PPMS, and novel anti-BMP for remyelination will be presented ECTRIMS 2019 to be held in Stockholm, Sweden on September 11-13 NESS ZIONA, Israel – September 4,...
Sterile injectable facility will enable the supply of commercial needs as part of the agreement with Mylan NESS ZIONA, Israel – July 15, 2019 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company announced today that is has...
Plant will enable Mapi to supply the initial commercial needs of GA Depot NESS ZIONA, Israel – March 18, 2019 – Mapi Pharma Ltd., a fully integrated, clinical, late stage biopharmaceutical company, announced today that it has received complementary funding from the...
Analyst Lunch and Live Webcast on Tuesday March 5th at 12 Noon ET NESS ZIONA, Israel – February 21, 2019 – Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, announced today that it will host a Key Opinion Leader (KOL) luncheon on its...
NESS ZIONA, Israel, November 5th, 2018. Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an equity investment of $10 million by Zhejiang Jingxin Pharmaceutical Co., Ltd. a publicly listed Chinese...
81.8% Patients on GA Depot Demonstrated No Evidence of Disease Activity (NEDA) at 2 years GA Depot Has Potential to Address Multiple Sclerosis Treatment Burden and Improve Patient Compliance NESS ZIONA, Israel – Oct. 9th, 2018 – Mapi Pharma Ltd., a fully integrated,... 